Recruitment completed in Dicot’s phase 1 trial
Press release: Uppsala, Sweden, March 11, 2024. Today, the potency drug developer Dicot announces that the recruitment to the final part of its phase 1 study is completed. The study is thus proceeding according to the previously communicated timeline and the results are expected to be announced during the second quarter.Dicot's phase 1 study, aiming at investigating the safety profile in humans, started in August 2023 and consists of two parts: SAD (single dose) and MAD (multiple doses). The study is placebo-controlled and double-blind, meaning that some participants receive LIB-01 and some